On March 29, Ge Longhui | Qianyuan Pharmaceutical (300254.SZ) was surveyed by a specific target on March 28, 2024, on “What is the sales situation of the company's smoking cessation drug vanicline tablets in 2023 and the expected future sales situation?” The company replied that in 2023, the company's smoking cessation drug varenicline tartrate sold more than 23 million yuan; with the continuous expansion of the company's dual-brand multi-channel sales of smoking cessation drugs, it is expected that the company's smoking cessation drugs will maintain a good growth trend in the future.
仟源医药(300254.SZ)：2023年公司戒烟药酒石酸伐尼克兰片销售2300余万元
Qianyuan Pharmaceutical (300254.SZ): In 2023, the company sold more than 23 million yuan of tobacco cessation drug varenicline tartrate tablets
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.